Hepatitis B Surface Antigen Quantification: Why and How to Use It in 2011- a Core Group Report
Resource
JOURNAL OF HEPATOLOGY v.55 n.5 pp.1121-1131
Journal
JOURNAL OF HEPATOLOGY
Journal Volume
v.55
Journal Issue
n.5
Pages
1121-1131
Date Issued
2011
Date
2011
Author(s)
CHAN, HENRY LIK-YUEN
KAO, JIA-HORNG
Abstract
Quantitative HBsAg had been suggested to be helpful in management of HBV, but assays were cumbersome. The recent availability of commercial quantitative assays has restarted the interest in quantitative serum hepatitis B surface antigen (HBsAg) as a biomarker for prognosis and treatment response in chronic hepatitis B. HBsAg level reflects the transcriptional activity of cccDNA rather than the absolute amount of cccDNA copies. Serum HBsAg level tends to be higher in hepatitis B e antigen (HBeAg)-positive than HBeAg- negative patients. Among patients with a low HBV DNA (<2000 IU/ml), HBsAg <1000 IU/ml in genotype D HBV infection and HBsAg <100 IU/ml in genotype B/C HBV infection is associated with inactive carrier state in HBeAg-negative patients. The HBsAg reduction by nucleos(t)ide analogues (NA) is not as pronounced as by interferon treatment. On peginterferon treatment, sustained responders tend to show greater HBsAg decline than the non-responders. The optimal on -treatment HBsAg cutoff to predict response needs further evaluation in HBeAg-positive patients, but an absence of HBsAg decline together with a < 2 log reduction in HBV DNA at week 12 can serve as stopping rule in HBeAg- negative patients with genotype D HBV infection. A rapid serum HBsAg decline during NA therapy may identify patients who will clear HBsAg in the long-term. There are early reports among Asian patients that an HBsAg level of <100 IU/ml might predict lower risk of relapse after stopping NA treatment. In clinical practice , serum HBsAg level should be used together with, but not as a substitute for, HBV DNA.
Subjects
Hepatitis B virus
HBsAg
Antiviral treatment
Peginterferon
SDGs